Newly released research has confirmed the efficacy of Natural Remedies’ Ashwa.30 in supporting stress regulation, physical endurance and post-exertion recovery.
Ashwa.30 is a low-dose, clinically studied ashwagandha root extract. The company has said that the new research will provide integrative practitioners with an evidence-based botanical tool aligned with personalised, systems-based care.
The study
The research involved a four-week, randomised, double-blind, placebo-controlled trial that evaluated 60 healthy adults experiencing elevated stress.
Participants receiving Ashwa.30 showed significantly improved physiological and psychological responses to stress compared with placebo, reinforcing the role of precision botanical extracts in clinical care.
"This data on Ashwa.30 gives clinicians objective markers to support stress resilience, physical performance and recovery," said Dr Suresh Lakshmikanthan, Chief Business Officer at Natural Remedies.
"It offers measurable reference points for practitioners working with patients experiencing fatigue, physical strain and chronic stress."
Under stress conditions, the Ashwa.30 group exhibited a lower cortisol response, with levels increasing 18.93% compared with an 86.17% increase in placebo.
Additional outcomes included a 44% reduction in DASS-21 stress scores, a ten per cent increase in VO2 max and reductions in markers of muscle damage and post-exertion fatigue.
The full findings have been submitted for peer-reviewed publication (Prajapati et al., 2025).
Additionally, supporting preclinical research using predictive transcriptomics also demonstrated Ashwa.30’s influence on gene expression associated with mitochondrial biogenesis and oxidative phosphorylation, pathways linked to cellular energy production and resilience.
Further findings from model organism studies indicate activity in pathways associated with oxidative stress regulation and cellular longevity.
The alignment of human clinical outcomes with mechanistic data may provide clinicians with additional context when evaluating botanical interventions within multidisciplinary care settings, including the use of validated stress scales and performance biomarkers.
"For integrative practitioners, mechanistic clarity is critical," added Lakshmikanthan.
"Understanding how an ingredient interacts with cellular energy systems helps bridge Eastern botanical traditions with Western clinical frameworks."
The study evaluated Ashwa.30 at a dose of 30 milligrams administered during a four-week period, providing practitioners with a clearly defined reference point when considering evidence-based botanical interventions for stress, recovery and performance support.
Natural Remedies will showcase Ashwa.30 and discuss the new clinical findings at the Integrative Healthcare Symposium from February 19-21, in New York City, providing healthcare practitioners an opportunity to review the evidence and engage directly with the company’s scientific team.